Tags

Type your tag names separated by a space and hit enter

Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis.
Antimicrob Agents Chemother. 2008 Dec; 52(12):4503-6.AA

Abstract

The participation of trypanothione in clinical and experimental antimony (Sb) resistance in Leishmania panamensis was examined by using specific inhibitors. Buthionine sulfoximine (BSO) significantly reversed the resistance to trivalent Sb (Sb(III)) of promastigotes of experimentally derived Sb-resistant lines, supporting the participation of a trypanothione-mediated mechanism of resistance. In contrast, promastigotes of strains isolated at the time of clinical treatment failure and resistant to pentavalent Sb (Sb(V)) as intracellular amastigotes were not cross resistant to Sb(III), and BSO had little or no effect on susceptibility. Difluoromethylornithine did not alter the Sb(III) susceptibilities of experimentally selected lines or clinical strains. The mechanisms of acquired resistance emerging in clinical settings may differ from those selected by in vitro exposure to Sb.

Authors+Show Affiliations

Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM), Avenida 1 Norte # 3-03, Cali, Colombia.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18824610

Citation

Goyeneche-Patino, Diego A., et al. "Antimony Resistance and Trypanothione in Experimentally Selected and Clinical Strains of Leishmania Panamensis." Antimicrobial Agents and Chemotherapy, vol. 52, no. 12, 2008, pp. 4503-6.
Goyeneche-Patino DA, Valderrama L, Walker J, et al. Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis. Antimicrob Agents Chemother. 2008;52(12):4503-6.
Goyeneche-Patino, D. A., Valderrama, L., Walker, J., & Saravia, N. G. (2008). Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis. Antimicrobial Agents and Chemotherapy, 52(12), 4503-6. https://doi.org/10.1128/AAC.01075-08
Goyeneche-Patino DA, et al. Antimony Resistance and Trypanothione in Experimentally Selected and Clinical Strains of Leishmania Panamensis. Antimicrob Agents Chemother. 2008;52(12):4503-6. PubMed PMID: 18824610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Antimony resistance and trypanothione in experimentally selected and clinical strains of Leishmania panamensis. AU - Goyeneche-Patino,Diego A, AU - Valderrama,Liliana, AU - Walker,John, AU - Saravia,Nancy G, Y1 - 2008/09/29/ PY - 2008/10/1/pubmed PY - 2009/1/28/medline PY - 2008/10/1/entrez SP - 4503 EP - 6 JF - Antimicrobial agents and chemotherapy JO - Antimicrob Agents Chemother VL - 52 IS - 12 N2 - The participation of trypanothione in clinical and experimental antimony (Sb) resistance in Leishmania panamensis was examined by using specific inhibitors. Buthionine sulfoximine (BSO) significantly reversed the resistance to trivalent Sb (Sb(III)) of promastigotes of experimentally derived Sb-resistant lines, supporting the participation of a trypanothione-mediated mechanism of resistance. In contrast, promastigotes of strains isolated at the time of clinical treatment failure and resistant to pentavalent Sb (Sb(V)) as intracellular amastigotes were not cross resistant to Sb(III), and BSO had little or no effect on susceptibility. Difluoromethylornithine did not alter the Sb(III) susceptibilities of experimentally selected lines or clinical strains. The mechanisms of acquired resistance emerging in clinical settings may differ from those selected by in vitro exposure to Sb. SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/18824610/Antimony_resistance_and_trypanothione_in_experimentally_selected_and_clinical_strains_of_Leishmania_panamensis_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=18824610 DB - PRIME DP - Unbound Medicine ER -